Sar9, Met (O2)11-Substance P
Also known as: [Sar9,Met(O2)11]-Substance P, Modified Substance P, NK1 agonist Substance P analog, Sar9-Met(O2)11-SP, Sar9, Met(O2)11‑SP
Source Sar9, Met (O2)11-Substance P at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Sar9, Met(O2)11‑Substance P is a chemically modified 11‑mer analogue of the endogenous neuropeptide Substance P, containing sarcosine at position 9 and a methionine sulfoxide at position 11. It is employed in pre‑clinical studies to probe NK1‑receptor pharmacology and to improve peptide stability.
Mechanism of Action
agonist of neurokinin‑1 (NK1) receptor, mimicking Substance P signaling
Routes of Administration
Goals & Uses
- NK1 receptor activation (research)Pharmacological ToolHigh
- NK1 receptor internalization assaysReceptor BiologyHigh
- NK1 receptor agonismPharmacologyModerate
- Neuroinflammation studiesInflammation ResearchModerate
- Nociception and pain researchNeuroscience ResearchModerate
- Peptide stability studiesFormulationModerate
- Pain pathway investigationResearchModerate
Contraindications
- Severe cardiovascular diseaseCardiovascularModerate
- Human therapeutic useRegulatory/safetyHigh
Adverse Effects
- HypotensionCardiovascularUnknownLow blood pressure
- Nociceptive behavior (hyperalgesia/allodynia)NeurologicalCommon
- BronchoconstrictionRespiratoryUnknown
- Plasma protein extravasation / edemaInflammatoryCommon
Drug Interactions
- NK1 receptor antagonists (e.g., aprepitant, L-703,606)High
- NK1 antagonists (e.g., aprepitant)High
Population Constraints
- General human populationRegulatory/safetyAbsolute
- Pregnant animalsReproductiveRelative
Regulatory Status
- European UnionUnapprovedNot authorized for clinical use.
- United StatesUnapprovedOnly available as a research chemical.
- United KingdomUnapprovedNo MHRA registration; research use only.
Not approved for any therapeutic indication; used solely as a research tool.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Sar9, Met (O2)11-Substance P?
Sar9, Met(O2)11‑Substance P is a chemically modified 11‑mer analogue of the endogenous neuropeptide Substance P, containing sarcosine at position 9 and a methionine sulfoxide at position 11. It is employed in pre‑clinical studies to probe NK1‑receptor pharmacology and to improve peptide stability.
What is Sar9, Met (O2)11-Substance P used for?
Sar9, Met (O2)11-Substance P is educationally associated with: NK1 receptor activation (research), NK1 receptor internalization assays, NK1 receptor agonism, Neuroinflammation studies, Nociception and pain research, Peptide stability studies, Pain pathway investigation. Educational only — not medical advice.
How is Sar9, Met (O2)11-Substance P administered?
Recorded routes of administration: Intracerebral, Intradermal, Intrathecal, Intravenous, Subcutaneous.
What are the potential side effects of Sar9, Met (O2)11-Substance P?
Reported adverse effects include: Hypotension, Nociceptive behavior (hyperalgesia/allodynia), Bronchoconstriction, Plasma protein extravasation / edema. This list is not exhaustive — consult a qualified clinician.
Who should avoid Sar9, Met (O2)11-Substance P?
Recorded contraindications: Severe cardiovascular disease, Human therapeutic use. Consult a qualified clinician before use.